The evaluation of gemcitabine in resistant or relapsing multiple myeloma, phase II: A Southwest Oncology Group Study

James K. Weick; John J. Crowley; Mohamed A. Hussein; Dennis F. Moore; Bart Barlogie

doi:10.1023/A:1014493007347

The evaluation of gemcitabine in resistant or relapsing multiple myeloma, phase II: A Southwest Oncology Group Study

James K. Weick, John J. Crowley, Mohamed A. Hussein, Dennis F. Moore, Bart Barlogie

Research output: Contribution to journal › Article › peer-review

12 Scopus citations

Abstract

Gemcitabine is a cytosine arabinoside (Ara-C) analog with activity in many human tumor systems. We evaluated the drug's activity in resistant or relapsing multiple myeloma. Gemcitabine 1000 mg/m² was administered as a 30 minute infusion on days 1, 8, and 15 of a 28-day cycle. No dose escalations were permitted and dose reductions were scheduled for hematologic toxicity. Twenty-nine eligible patients were entered into Southwest Oncology Group (SWOG)-9803. One patient received no treatment and 5 patients had inadequate response assessments. The major toxicity was hematologic with grade 3/4 neutropenia in 9 and grade 3/4 thrombocytopenia in 15 patients. No responses were seen. Stable disease was confirmed in sixteen patients (57%). Median survival was eight months. Gemcitabine as utilized in this trial has shown little activity and is not to be strongly considered for future multiple myeloma trials.

Original language	English
Pages (from-to)	117-121
Number of pages	5
Journal	Investigational New Drugs
Volume	20
Issue number	1
DOIs	https://doi.org/10.1023/A:1014493007347
State	Published - 2002
Externally published	Yes

Keywords

Gemcitabine
Multiple myeloma
Phase II

Access to Document

10.1023/A:1014493007347

Cite this

@article{6f79183559e44add9ee427563a1d4528,

title = "The evaluation of gemcitabine in resistant or relapsing multiple myeloma, phase II: A Southwest Oncology Group Study",

abstract = "Gemcitabine is a cytosine arabinoside (Ara-C) analog with activity in many human tumor systems. We evaluated the drug's activity in resistant or relapsing multiple myeloma. Gemcitabine 1000 mg/m2 was administered as a 30 minute infusion on days 1, 8, and 15 of a 28-day cycle. No dose escalations were permitted and dose reductions were scheduled for hematologic toxicity. Twenty-nine eligible patients were entered into Southwest Oncology Group (SWOG)-9803. One patient received no treatment and 5 patients had inadequate response assessments. The major toxicity was hematologic with grade 3/4 neutropenia in 9 and grade 3/4 thrombocytopenia in 15 patients. No responses were seen. Stable disease was confirmed in sixteen patients (57%). Median survival was eight months. Gemcitabine as utilized in this trial has shown little activity and is not to be strongly considered for future multiple myeloma trials.",

keywords = "Gemcitabine, Multiple myeloma, Phase II",

author = "Weick, {James K.} and Crowley, {John J.} and Hussein, {Mohamed A.} and Moore, {Dennis F.} and Bart Barlogie",

note = "Funding Information: CA38926, CA32102, CA04919, CA35431, CA37981, CA13612, CA45450, CA35178, CA58416, CA35176, CA52386, CA58861, CA14028, CA42777, CA68183, CA35261, CA35262, CA12644, CA27057, CA35281, CA46113, CA35128, CA58415, and supported in part by Eli Lilly and Company. Funding Information: This investigation was supported in part by the following PHS Cooperative Agreement grant numbers awarded by the National Cancer Institute, DHHS:",

year = "2002",

doi = "10.1023/A:1014493007347",

language = "English",

volume = "20",

pages = "117--121",

journal = "Investigational New Drugs",

issn = "0167-6997",

publisher = "Springer",

number = "1",

}

TY - JOUR

T1 - The evaluation of gemcitabine in resistant or relapsing multiple myeloma, phase II

T2 - A Southwest Oncology Group Study

AU - Weick, James K.

AU - Crowley, John J.

AU - Hussein, Mohamed A.

AU - Moore, Dennis F.

AU - Barlogie, Bart

N1 - Funding Information: CA38926, CA32102, CA04919, CA35431, CA37981, CA13612, CA45450, CA35178, CA58416, CA35176, CA52386, CA58861, CA14028, CA42777, CA68183, CA35261, CA35262, CA12644, CA27057, CA35281, CA46113, CA35128, CA58415, and supported in part by Eli Lilly and Company. Funding Information: This investigation was supported in part by the following PHS Cooperative Agreement grant numbers awarded by the National Cancer Institute, DHHS:

PY - 2002

Y1 - 2002

N2 - Gemcitabine is a cytosine arabinoside (Ara-C) analog with activity in many human tumor systems. We evaluated the drug's activity in resistant or relapsing multiple myeloma. Gemcitabine 1000 mg/m2 was administered as a 30 minute infusion on days 1, 8, and 15 of a 28-day cycle. No dose escalations were permitted and dose reductions were scheduled for hematologic toxicity. Twenty-nine eligible patients were entered into Southwest Oncology Group (SWOG)-9803. One patient received no treatment and 5 patients had inadequate response assessments. The major toxicity was hematologic with grade 3/4 neutropenia in 9 and grade 3/4 thrombocytopenia in 15 patients. No responses were seen. Stable disease was confirmed in sixteen patients (57%). Median survival was eight months. Gemcitabine as utilized in this trial has shown little activity and is not to be strongly considered for future multiple myeloma trials.

AB - Gemcitabine is a cytosine arabinoside (Ara-C) analog with activity in many human tumor systems. We evaluated the drug's activity in resistant or relapsing multiple myeloma. Gemcitabine 1000 mg/m2 was administered as a 30 minute infusion on days 1, 8, and 15 of a 28-day cycle. No dose escalations were permitted and dose reductions were scheduled for hematologic toxicity. Twenty-nine eligible patients were entered into Southwest Oncology Group (SWOG)-9803. One patient received no treatment and 5 patients had inadequate response assessments. The major toxicity was hematologic with grade 3/4 neutropenia in 9 and grade 3/4 thrombocytopenia in 15 patients. No responses were seen. Stable disease was confirmed in sixteen patients (57%). Median survival was eight months. Gemcitabine as utilized in this trial has shown little activity and is not to be strongly considered for future multiple myeloma trials.

KW - Gemcitabine

KW - Multiple myeloma

KW - Phase II

UR - http://www.scopus.com/inward/record.url?scp=0036210569&partnerID=8YFLogxK

U2 - 10.1023/A:1014493007347

DO - 10.1023/A:1014493007347

M3 - Article

C2 - 12003187

AN - SCOPUS:0036210569

SN - 0167-6997

VL - 20

SP - 117

EP - 121

JO - Investigational New Drugs

JF - Investigational New Drugs

IS - 1

ER -

The evaluation of gemcitabine in resistant or relapsing multiple myeloma, phase II: A Southwest Oncology Group Study

Abstract

Keywords

Access to Document

Fingerprint

Cite this